slides · global inventory
Sequoia Pitch
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 43,093
Current window 19,171-19,200
Pages 1,437
Rows per page 30
Arc
19,171-19,200 of 43,093
19
The slide outlines a two-stage process: Mutation discovery (sequencing, analysis, identification, validation) followed by Immunogenicity testing (peptide immunization and ELISPOT).BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Solution OverviewLoop · Logic Chain1 hit
20
The slide uses a biological process diagram on the left and a scatter plot of mutation burden across cancer types on the right.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Solution OverviewLoop · Logic Chain1 hit
60
BioNTech | Investor Day Presentation Deck | 156 slidesBioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Market Opportunity1 hit
61
The slide uses a three-column layout to present the problem, with a footer section listing the company's solutions.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Market Opportunity1 hit
62
BioNTech | Investor Day Presentation Deck | 156 slidesBioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Market Opportunity1 hit
63
FIH stands for first-in-human.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Market Opportunity1 hit
64
BioNTech | Investor Day Presentation Deck | 156 slidesBioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Market Opportunity1 hit
65
The slide uses a before-after framing to contrast efficacy and safety data.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Market Opportunity1 hit
66
The slide uses a timeline-like progression of vaccine development stages.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Market Opportunity1 hit
67
The table highlights that all tested Omicron-modified vaccines met the superiority criterion (lower bound of 95% CI for GMR > 1.0).BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Market Opportunity1 hit
68
The table highlights that all tested Omicron-modified vaccines met the super superiority criterion (GMR lower bound > 1.5).BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Market Opportunity1 hit
69
The table highlights the seroresponse difference and non-inferiority status for participants without prior infection.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Market Opportunity1 hit
70
The chart compares baseline (Prevax 1MPD) vs post-vaccination GMTs for various BNT162b2 and Bivalent formulations.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Market Opportunity1 hit
91
The slide features a portrait of Özlem Türeci, co-founder and Chief Medical Officer of BioNTech.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Product Pipeline1 hit
92
The slide maps biological interactions (APC, T cell, Tumor cells) to numbered therapeutic interventions.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Product Pipeline1 hit
93
The slide uses a Gantt-style visualization for clinical trial phases.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Product Pipeline1 hit
94
The slide uses a process-flow style to show how different modalities combine to produce specific clinical outcomes.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Product Pipeline1 hit
95
The slide features a stylized, microscopic-style illustration of a molecular structure.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Product Pipeline1 hit
96
The slide uses a biological process diagram to explain the mechanism of action and a branching logic diagram to explain the product portfolio strategy.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Product Pipeline1 hit
97
The slide uses a circular process flow for the 5 steps and a feedback loop for the continuous platform evolution.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Product Pipeline1 hit
98
Includes process flow, flow cytometry data, and scatter plot of TCR frequency.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Product Pipeline1 hit
99
The slide uses a comparison table to contrast early-line vs late-line settings across three key biological dimensions.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Product Pipeline1 hit
100
Clinical trial design diagram showing patient flow, randomization, and treatment arms.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Product Pipeline1 hit
101
The slide uses a process flow diagram to illustrate the current patient journey and outcomes.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Product Pipeline1 hit
102
The slide uses a process flow diagram to illustrate the clinical trial patient journey from screening to randomization and treatment arms.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Product Pipeline1 hit
103
The slide uses a timeline diagram to show the treatment protocol and lists to summarize clinical context.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Product Pipeline1 hit
104
Includes a pie chart of responder status and a line chart showing T-cell expansion over time, plus a summary table of median T-cell percentages.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Product Pipeline1 hit
105
Shows stacked bar chart of neoantigen immunogenicity and a line chart of IFNy spots over time for responders.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Product Pipeline1 hit
106
Kaplan-Meier plot showing significant difference in RFS between responders and non-responders.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Product Pipeline1 hit
107
The slide illustrates the modular nature of the FixVac platform, showing how different antigen cassettes are used for specific cancers (Melanoma, HPV16+ HNSCC, Prostate cancer, NSCLC).BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Product Pipeline1 hit